Micro
Emerging
Active
MDCXW FDA progress e prospettive cliniche di espansione
Nuova narrativa con copertura limitata — ancora in formazione.
Punteggio
0,5
Velocità
▲ 0,0
Articoli
1
Fonti
1
Cronologia del Sentiment
Cronologia degli Eventi
Mag 19, 2026
Medicus Pharma Ltd. (MDCXW) Reports FDA Progress and Expands 2026 Clinical Outlook
Neutral
Ipotesi
Pending
Scadenza: 18 Luglio 2026
MDCXW trading volume will increase by at least 40% average daily volume in the 30 days following FDA progress announcement compared to 30-day pre-announcement baseline
Pending
Scadenza: 15 Novembre 2026
MDCXW will complete enrollment for at least one Phase 2 or Phase 3 clinical trial by end of Q2 2026, as evidenced by regulatory filings or company announcements
Pending
Scadenza: 17 Agosto 2026
MDCXW stock price will appreciate by at least 15% within 90 days following positive FDA feedback on clinical trial progression announced in Q1 2026
Cronologia
Ultimo aggiornamentoMag 19, 2026